{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:20:23Z","timestamp":1790497223554,"version":"4.1.0"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006111","name":"Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000054"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000054"]}],"id":[{"id":"10.13039\/501100006111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["SFRH\/BD\/2020.04932"],"award-info":[{"award-number":["SFRH\/BD\/2020.04932"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimie"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.biochi.2022.08.003","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T14:42:50Z","timestamp":1660142570000},"page":"123-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The current state of amyloidosis therapeutics and the potential role of fluorine in their treatment"],"prefix":"10.1016","volume":"202","author":[{"given":"Meghna","family":"Dabur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9841-3967","authenticated-orcid":false,"given":"Joana A.","family":"Loureiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmo","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biochi.2022.08.003_bib1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev.biochem.75.101304.123901","article-title":"Protein misfolding, functional amyloid, and human disease","volume":"75","author":"Chiti","year":"2006","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.biochi.2022.08.003_bib2","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/cbic.200900666","article-title":"Strategies for the inhibition of protein aggregation in human diseases","volume":"11","author":"Bartolini","year":"2010","journal-title":"Chembiochem : a Eur. j. chem. biol."},{"key":"10.1016\/j.biochi.2022.08.003_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-biochem-061516-045115","article-title":"Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade","volume":"86","author":"Chiti","year":"2017","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.biochi.2022.08.003_bib4","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000506696","article-title":"The pathology of amyloidosis in classification: a review","volume":"143","author":"Picken","year":"2020","journal-title":"Acta Haematol."},{"key":"10.1016\/j.biochi.2022.08.003_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111826","article-title":"Applications of fluorine-containing amino acids for drug design","volume":"186","author":"Mei","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biochi.2022.08.003_bib6","doi-asserted-by":"crossref","first-page":"9552","DOI":"10.1039\/C7OB02094E","article-title":"Synthesis and biological applications of fluoro-modified nucleic acids","volume":"15","author":"Guo","year":"2017","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.biochi.2022.08.003_bib7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jfluchem.2006.06.007","article-title":"Fluorine in medicinal chemistry: recent therapeutic applications of fluorinated small molecules","volume":"127","author":"Kirk","year":"2006","journal-title":"J.\u00a0Fluor. Chem."},{"key":"10.1016\/j.biochi.2022.08.003_bib8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/14756360701425014","article-title":"The role of fluorine in medicinal chemistry","volume":"22","author":"Shah","year":"2007","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.biochi.2022.08.003_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.25751","article-title":"Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biochi.2022.08.003_bib10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s40265-015-0389-7","article-title":"Safinamide: first global approval","volume":"75","author":"Deeks","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.biochi.2022.08.003_bib11","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.drudis.2018.01.033","article-title":"Safinamide: a new hope for Parkinson's disease?","volume":"23","author":"Teixeira","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biochi.2022.08.003_bib12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1021\/ml1000239","article-title":"Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable \u03b3-secretase inhibitor","volume":"1","author":"Gillman","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.biochi.2022.08.003_bib13","doi-asserted-by":"crossref","first-page":"7437","DOI":"10.1073\/pnas.89.16.7437","article-title":"Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4\/beta protein","volume":"89","author":"Knauer","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.biochi.2022.08.003_bib14","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1021\/jp9102993","article-title":"The thermodynamic stability of amyloid fibrils studied by differential scanning calorimetry","volume":"114","author":"Morel","year":"2010","journal-title":"J.\u00a0Phys. Chem. B"},{"key":"10.1016\/j.biochi.2022.08.003_bib15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00109-013-1025-1","article-title":"The role of amyloidogenic protein oligomerization in neurodegenerative disease","volume":"91","author":"Lotz","year":"2013","journal-title":"J.\u00a0Mol. Med."},{"key":"10.1016\/j.biochi.2022.08.003_bib16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.neuro.26.010302.081142","article-title":"Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders","volume":"26","author":"Caughey","year":"2003","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.biochi.2022.08.003_bib17","first-page":"101","article-title":"Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide, Nature reviews","volume":"8","author":"Haass","year":"2007","journal-title":"Mol. cell biol."},{"key":"10.1016\/j.biochi.2022.08.003_bib18","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.febslet.2009.05.005","article-title":"Glimpses of the molecular mechanisms of beta2-microglobulin fibril formation in\u00a0vitro: aggregation on a complex energy landscape","volume":"583","author":"Platt","year":"2009","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biochi.2022.08.003_bib19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jmb.2012.02.031","article-title":"From macroscopic measurements to microscopic mechanisms of protein aggregation","volume":"421","author":"Cohen","year":"2012","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.biochi.2022.08.003_bib20","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1126\/science.1178250","article-title":"An analytical solution to the kinetics of breakable filament assembly","volume":"326","author":"Knowles","year":"2009","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.biochi.2022.08.003_bib21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1042\/BST20120134","article-title":"Tau oligomers and tau toxicity in neurodegenerative disease","volume":"40","author":"Ward","year":"2012","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.biochi.2022.08.003_bib22","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ijbiomac.2021.03.113","article-title":"The role of amyloid oligomers in neurodegenerative pathologies","volume":"181","author":"Wells","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.biochi.2022.08.003_bib23","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jmb.2005.08.066","article-title":"Molecular dynamics simulations of alzheimer's \u03b2-amyloid protofilaments","volume":"353","author":"Buchete","year":"2005","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.biochi.2022.08.003_bib24","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1021\/acschemneuro.7b00409","article-title":"Thermodynamics of amyloid-\u03b2 fibril elongation: atomistic details of the transition state","volume":"9","author":"Rodriguez","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biochi.2022.08.003_bib25","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3390\/ijms22041859","article-title":"Promotion and inhibition of amyloid-\u03b2 peptide aggregation: molecular dynamics studies","volume":"22","author":"Itoh","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biochi.2022.08.003_bib26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1021\/jacs.7b10343","article-title":"Pathways of amyloid-\u03b2 aggregation depend on oligomer shape","volume":"140","author":"Barz","year":"2018","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.biochi.2022.08.003_bib27","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1074\/jbc.M808591200","article-title":"Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer","volume":"284","author":"Kayed","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.biochi.2022.08.003_bib28","doi-asserted-by":"crossref","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","article-title":"\u03b1-Synuclein in Parkinson's disease","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold Spring Harbor Perspect. Med."},{"key":"10.1016\/j.biochi.2022.08.003_bib29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/JAD-2010-1221","article-title":"Alzheimer's disease and the amyloid-beta peptide","volume":"19","author":"Murphy","year":"2010","journal-title":"J.\u00a0Alzheim. Dis. : JAD"},{"key":"10.1016\/j.biochi.2022.08.003_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2011.12.013","article-title":"Protein aggregates in Huntington's disease","volume":"238","author":"Arrasate","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.biochi.2022.08.003_bib31","first-page":"11","article-title":"Prion and prion-like protein strains: deciphering the molecular basis of heterogeneity in neurodegeneration","author":"Scial\u00f2","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.biochi.2022.08.003_bib32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0140-6736(11)60207-9","article-title":"Management of type 2 diabetes: new and future developments in treatment","volume":"378","author":"Tahrani","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.biochi.2022.08.003_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/humu.10100","article-title":"Familial conformational diseases and dementias","volume":"20","author":"Crowther","year":"2002","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.biochi.2022.08.003_bib34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bmcl.2018.12.049","article-title":"New evolutions in the BACE1 inhibitor field from 2014 to 2018","volume":"29","author":"Hsiao","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.biochi.2022.08.003_bib35","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3233\/JAD-160829","article-title":"BACE1 dynamics upon inhibition with a BACE inhibitor and correlation to downstream alzheimer's disease markers in elderly healthy participants","volume":"56","author":"Timmers","year":"2017","journal-title":"J.\u00a0Alzheim. Dis."},{"key":"10.1016\/j.biochi.2022.08.003_bib36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jnc.12715","article-title":"Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects","volume":"130","author":"Vassar","year":"2014","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.biochi.2022.08.003_bib37","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.biochi.2022.08.003_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: beyond RNA interference and antisense oligonucleotides","volume":"11","author":"Kole","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biochi.2022.08.003_bib39","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/mt.2009.306","article-title":"Novel RNA-based strategies for therapeutic gene silencing","volume":"18","author":"Sibley","year":"2010","journal-title":"Mol. Ther. : J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.biochi.2022.08.003_bib40","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3727\/096368914X678454","article-title":"Polyglutamine (PolyQ) diseases: genetics to treatments","volume":"23","author":"Fan","year":"2014","journal-title":"Cell Transplant."},{"key":"10.1016\/j.biochi.2022.08.003_bib41","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00109-013-1016-2","article-title":"RNA toxicity in polyglutamine disorders: concepts, models, and progress of research","volume":"91","author":"Fiszer","year":"2013","journal-title":"J.\u00a0Mol. Med."},{"key":"10.1016\/j.biochi.2022.08.003_bib42","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of huntington's disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.biochi.2022.08.003_bib43","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","article-title":"Inotersen: first global approval","volume":"78","author":"Keam","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.biochi.2022.08.003_bib44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.biochi.2022.08.003_bib45","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: first global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.biochi.2022.08.003_bib46","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrd.2018.133","article-title":"Therapeutic approaches to Huntington disease: from the bench to the clinic","volume":"17","author":"Caron","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biochi.2022.08.003_bib47","first-page":"185","article-title":"Huntington's disease clinical trials corner: april 2020","volume":"9","author":"Rodrigues","year":"2020","journal-title":"J.\u00a0Huntingt. Dis."},{"key":"10.1016\/j.biochi.2022.08.003_bib48","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington's disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.biochi.2022.08.003_bib49","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","article-title":"AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a huntington's disease minipig model","volume":"26","author":"Evers","year":"2018","journal-title":"Mol. Ther. : J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.biochi.2022.08.003_bib50","article-title":"Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington's disease, Molecular therapy","volume":"3","author":"Hadaczek","year":"2016","journal-title":"Methods & clin. dev."},{"key":"10.1016\/j.biochi.2022.08.003_bib51","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.omtm.2019.09.010","article-title":"AAV5-miHTT lowers huntingtin mRNA and protein without off-target effects in patient-derived neuronal cultures and astrocytes, molecular therapy","volume":"15","author":"Keskin","year":"2019","journal-title":"Methods & clin. dev."},{"key":"10.1016\/j.biochi.2022.08.003_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biochi.2022.08.003_bib53","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/978-1-4939-7825-0_21","article-title":"CRISPR\/Cas9-Mediated genome editing for huntington's disease","volume":"1780","author":"Vachey","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biochi.2022.08.003_bib54","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.1021\/jp1116728","article-title":"Inhibition of aggregation of amyloid peptides by beta-sheet breaker peptides and their binding affinity","volume":"115","author":"Viet","year":"2011","journal-title":"J.\u00a0Phys. Chem. B"},{"key":"10.1016\/j.biochi.2022.08.003_bib55","doi-asserted-by":"crossref","first-page":"11242","DOI":"10.1074\/jbc.M113.537472","article-title":"Computational and experimental studies on#2-sheet breakers targeting D2Q 40 fibrils","volume":"289","author":"Minicozzi","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.biochi.2022.08.003_bib56","doi-asserted-by":"crossref","first-page":"8139","DOI":"10.1038\/srep08139","article-title":"Rationally designed peptidomimetic modulators of A\u03b2 toxicity in alzheimer's disease","volume":"5","author":"Rajasekhar","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biochi.2022.08.003_bib57","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1039\/C3TB21483D","article-title":"Fluorinated beta-sheet breaker peptides","volume":"2","author":"Loureiro","year":"2014","journal-title":"J.\u00a0Mater. Chem. B"},{"key":"10.1016\/j.biochi.2022.08.003_bib58","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/1471-2105-8-451","article-title":"Peptide ligand screening of \u03b1-synuclein aggregation modulators by in silico panning","volume":"8","author":"Abe","year":"2007","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.biochi.2022.08.003_bib59","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.1021\/ja075356q","article-title":"Design of an N-methylated peptide inhibitor of \u03b1-synuclein aggregation guided by solid-state NMR","volume":"130","author":"Madine","year":"2008","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.biochi.2022.08.003_bib60","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(99)11419-3","article-title":"Reversion of prion protein conformational changes by synthetic b-sheet breaker peptides","volume":"355","author":"Soto","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.biochi.2022.08.003_bib61","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s13311-013-0184-7","article-title":"Inhibition of protein misfolding\/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases","volume":"10","author":"Popiel","year":"2013","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.biochi.2022.08.003_bib62","article-title":"Mimicking molecular chaperones to regulate protein folding","volume":"32","author":"Ma","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biochi.2022.08.003_bib63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrn1587","article-title":"Modulation of neurodegeneration by molecular chaperones","volume":"6","author":"Muchowski","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.biochi.2022.08.003_bib64","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1074\/jbc.M412106200","article-title":"Mechanisms of suppression of {alpha}-Synuclein neurotoxicity by geldanamycin in Drosophila","volume":"280","author":"Auluck","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.biochi.2022.08.003_bib65","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/nm1298","article-title":"17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration","volume":"11","author":"Waza","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.biochi.2022.08.003_bib66","doi-asserted-by":"crossref","first-page":"38183","DOI":"10.1074\/jbc.M110.160218","article-title":"Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle","volume":"285","author":"Lotz","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.biochi.2022.08.003_bib67","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jmb.2012.02.003","article-title":"DnaJA1 antagonizes constitutive Hsp70-mediated stabilization of tau","volume":"421","author":"Abisambra","year":"2012","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.biochi.2022.08.003_bib68","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1002\/jnr.21417","article-title":"Molecular chaperone-mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain","volume":"85","author":"Sahara","year":"2007","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.biochi.2022.08.003_bib69","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1471-4159.2008.05595.x","article-title":"Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1G93A mouse model of ALS","volume":"107","author":"Kalmar","year":"2008","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.biochi.2022.08.003_bib70","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nm1021","article-title":"Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice","volume":"10","author":"Kieran","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.biochi.2022.08.003_bib71","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/157340708786305952","article-title":"Iron chelators as potential therapeutic agents for Parkinson's disease","volume":"4","author":"Perez","year":"2008","journal-title":"Curr. Bioact. Compd."},{"key":"10.1016\/j.biochi.2022.08.003_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017669","article-title":"Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease","volume":"6","author":"Adlard","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.biochi.2022.08.003_bib73","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1471-4159.2011.07402.x","article-title":"The Alzheimer's therapeutic PBT2 promotes amyloid-\u03b2 degradation and GSK3 phosphorylation via a metal chaperone activity","volume":"119","author":"Crouch","year":"2011","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.biochi.2022.08.003_bib74","first-page":"779","article-title":"Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial, the Lancet","volume":"7","author":"Lannfelt","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.biochi.2022.08.003_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120150","article-title":"Artificial chaperones: from materials designs to applications","volume":"254","author":"Hanpanich","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.biochi.2022.08.003_bib76","first-page":"1","article-title":"Mimicking molecular chaperones to regulate protein folding","volume":"32","author":"Ma","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biochi.2022.08.003_bib77","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","article-title":"Active and passive immunotherapy for neurodegenerative disorders","volume":"31","author":"Brody","year":"2008","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.biochi.2022.08.003_bib78","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.biochi.2022.08.003_bib79","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","article-title":"Active and passive immunotherapy for neurodegenerative disorders","volume":"31","author":"Brody","year":"2008","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.biochi.2022.08.003_bib80","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-021-00838-z","article-title":"Aducanumab produced a clinically meaningful benefit in association with amyloid lowering","volume":"13","author":"Cummings","year":"2021","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.biochi.2022.08.003_bib81","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A\u00a0randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.biochi.2022.08.003_bib82","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-Amyloid-\u03b2 monoclonal antibodies for Alzheimer's disease: pitfalls and promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.biochi.2022.08.003_bib83","doi-asserted-by":"crossref","first-page":"629","DOI":"10.4103\/0253-7613.194867","article-title":"Novel strategies for Alzheimer's disease treatment: an overview of anti-amyloid beta monoclonal antibodies","volume":"48","author":"Rygiel","year":"2016","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.biochi.2022.08.003_bib84","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of Solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.biochi.2022.08.003_bib85","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1523\/JNEUROSCI.3192-13.2014","article-title":"Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles","volume":"34","author":"Castillo-Carranza","year":"2014","journal-title":"J.\u00a0Neurosci. : Off. J. Soc. Neurosci."},{"key":"10.1016\/j.biochi.2022.08.003_bib86","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1021\/acs.biochem.6b00149","article-title":"Structural effects of two camelid nanobodies directed to distinct C-terminal epitopes on \u03b1-synuclein","volume":"55","author":"El-Turk","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.biochi.2022.08.003_bib87","doi-asserted-by":"crossref","first-page":"11041","DOI":"10.1021\/bi8005797","article-title":"Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrils","volume":"47","author":"Chan","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.biochi.2022.08.003_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/srep46711","article-title":"A\u00a0specific nanobody prevents amyloidogenesis of D76N \u03b2(2)-microglobulin in\u00a0vitro and modifies its tissue distribution in\u00a0vivo","volume":"7","author":"Raimondi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biochi.2022.08.003_bib89","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1073\/pnas.1111232108","article-title":"Structure-based design of conformation- and sequence-specific antibodies against amyloid \u03b2","volume":"109","author":"Perchiacca","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.biochi.2022.08.003_bib90","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/cbic.201402552","article-title":"A\u00a0\u03b2-hairpin-binding protein for three different disease-related amyloidogenic proteins","volume":"16","author":"Shaykhalishahi","year":"2015","journal-title":"Chembiochem : a Eur. j. chem. biol."},{"key":"10.1016\/j.biochi.2022.08.003_bib91","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1073\/pnas.0711731105","article-title":"Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-beta peptide inhibits amyloid formation","volume":"105","author":"Hoyer","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.biochi.2022.08.003_bib92","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1002\/anie.201309001","article-title":"Sequestration of a \u03b2-hairpin for control of \u03b1-synuclein aggregation","volume":"53","author":"Mirecka","year":"2014","journal-title":"Angew. Chem."},{"key":"10.1016\/j.biochi.2022.08.003_bib93","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.neuron.2010.08.044","article-title":"Acetylation of tau inhibits its degradation and contributes to tauopathy","volume":"67","author":"Min","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.biochi.2022.08.003_bib94","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.biochi.2022.08.003_bib95","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cell.2009.03.018","article-title":"Acetylation targets mutant huntingtin to autophagosomes for degradation","volume":"137","author":"Jeong","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.biochi.2022.08.003_bib96","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1073858410390378","article-title":"Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease","volume":"17","author":"Ehrnhoefer","year":"2011","journal-title":"Neuroscientist : rev. j. bringing neurobiol. neurol. psychiatr."},{"key":"10.1016\/j.biochi.2022.08.003_bib97","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/ndt\/gfv048","article-title":"Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease","volume":"30","author":"Gajjala","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.biochi.2022.08.003_bib98","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.colsurfb.2011.11.036","article-title":"Modulation of pathway of insulin fibrillation by a small molecule helix inducer 2,2,2-trifluoroethanol","volume":"92","author":"Banerjee","year":"2012","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.biochi.2022.08.003_bib99","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.3390\/ijms21082989","article-title":"Fluorinated molecules and nanotechnology: future \u2018avengers\u2019 against the Alzheimer's disease?","volume":"21","author":"Dabur","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biochi.2022.08.003_bib100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S1570-9639(02)00461-2","article-title":"Change and stabilization of the amyloid-\u03b2(1\u201340) secondary structure by fluorocompounds","volume":"1645","author":"Vieira","year":"2003","journal-title":"Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"},{"key":"10.1016\/j.biochi.2022.08.003_bib101","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/bip.22670","article-title":"(R)-\u03b1-trifluoromethylalanine containing short peptide in the inhibition of amyloid peptide fibrillation","volume":"104","author":"Botz","year":"2015","journal-title":"Peptide Science"},{"key":"10.1016\/j.biochi.2022.08.003_bib102","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1021\/bi0601104","article-title":"Organofluorine inhibitors of amyloid fibrillogenesis","volume":"45","author":"T\u00f6r\u00f6k","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.biochi.2022.08.003_bib103","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jmgm.2016.11.013","article-title":"The effects of fluorine substitution on the chemical properties and inhibitory capacity of Donepezil anti-Alzheimer drug; density functional theory and molecular docking calculations","volume":"71","author":"Khosravan","year":"2017","journal-title":"J.\u00a0Mol. Graph. Model."},{"key":"10.1016\/j.biochi.2022.08.003_bib104","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1021\/jm400225m","article-title":"\u03b2-Secretase (BACE1) inhibitors with high in\u00a0vivo efficacy suitable for clinical evaluation in Alzheimer's disease","volume":"56","author":"Hilpert","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.biochi.2022.08.003_bib105","doi-asserted-by":"crossref","first-page":"7234","DOI":"10.1021\/acs.jmedchem.8b00644","article-title":"Design, synthesis, and biological evaluation of novel 7-[(3 aS,7 aS)-3 a-aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens","volume":"61","author":"Odagiri","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.biochi.2022.08.003_bib106","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.bmcl.2018.01.056","article-title":"Diastereoselective synthesis of fused cyclopropyl-3-amino-2,4-oxazine \u03b2-amyloid cleaving enzyme (BACE) inhibitors and their biological evaluation","volume":"28","author":"Low","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.biochi.2022.08.003_bib107","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1016\/j.bmcl.2013.05.003","article-title":"BACE1 inhibitors: a head group scan on a series of amides","volume":"23","author":"Woltering","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.biochi.2022.08.003_bib108","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1007\/s11064-021-03344-8","article-title":"Volatile anesthetic sevoflurane precursor 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) exerts an anti-prion activity in prion-infected culture cells","volume":"46","author":"Shimizu","year":"2021","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.biochi.2022.08.003_bib109","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0006-3495(99)77270-X","article-title":"Ultrastructural studies on scrapie prion protein crystals obtained from reverse micellar solutions","volume":"76","author":"Wille","year":"1999","journal-title":"Biophys. J."},{"key":"10.1016\/j.biochi.2022.08.003_bib110","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1074\/jbc.M410553200","article-title":"Amyloid-\u03b2 protofibrils differ from amyloid-\u03b2 aggregates induced in dilute hexafluoroisopropanol in stability and morphology \u2217","volume":"280","author":"Nichols","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.biochi.2022.08.003_bib111","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ab.2015.12.021","article-title":"Nuclear magnetic resonance evidence for the dimer formation of beta amyloid peptide 1\u201342 in 1,1,1,3,3,3-hexafluoro-2-propanol","volume":"498","author":"Shigemitsu","year":"2016","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.biochi.2022.08.003_bib112","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/1062936X.2013.773374","article-title":"QSAR prediction of the competitive interaction of emerging halogenated pollutants with human transthyretin","volume":"24","author":"Papa","year":"2013","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.biochi.2022.08.003_bib113","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tox.2016.08.011","article-title":"Binding interactions of perfluoroalkyl substances with thyroid hormone transport proteins and potential toxicological implications","volume":"366\u2013367","author":"Ren","year":"2016","journal-title":"Toxicology"},{"key":"10.1016\/j.biochi.2022.08.003_bib114","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/toxsci\/kfp055","article-title":"Competitive binding of poly- and perfluorinated compounds to the thyroid hormone transport protein transthyretin","volume":"109","author":"Weiss","year":"2009","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.biochi.2022.08.003_bib115","doi-asserted-by":"crossref","first-page":"11293","DOI":"10.1021\/es4026722","article-title":"Structure-based investigation on the interaction of perfluorinated compounds with human liver fatty acid binding protein","volume":"47","author":"Zhang","year":"2013","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.biochi.2022.08.003_bib116","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.chemosphere.2017.05.016","article-title":"Different binding mechanisms of neutral and anionic poly-\/perfluorinated chemicals to human transthyretin revealed by in silico models","volume":"182","author":"Yang","year":"2017","journal-title":"Chemosphere"},{"key":"10.1016\/j.biochi.2022.08.003_bib117","doi-asserted-by":"crossref","first-page":"5656","DOI":"10.1021\/ja311729d","article-title":"Aromatic sulfonyl fluorides covalently kinetically stabilize transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate","volume":"135","author":"Grimster","year":"2013","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.biochi.2022.08.003_bib118","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2337\/diabetes.48.2.241","article-title":"Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes","volume":"48","author":"Kahn","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.biochi.2022.08.003_bib119","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1002\/cbic.202000373","article-title":"The impact of halogenated phenylalanine derivatives on NFGAIL amyloid formation","volume":"21","author":"Chowdhary","year":"2020","journal-title":"Chembiochem : a Eur. j. chem. biol."},{"key":"10.1016\/j.biochi.2022.08.003_bib120","first-page":"759","article-title":"Silencing of genes responsible for polyQ diseases using chemically modified single-stranded siRNAs","volume":"63","author":"Fiszer","year":"2016","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.biochi.2022.08.003_bib121","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jmb.2006.08.030","article-title":"Mechanism by which the amyloid-like fibrils of a \u03b22-microglobulin fragment are induced by fluorine-substituted alcohols","volume":"363","author":"Yamaguchi","year":"2006","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.biochi.2022.08.003_bib122","doi-asserted-by":"crossref","first-page":"22827","DOI":"10.1074\/jbc.M111.333310","article-title":"Polymorphism of microglobulin amyloid fibrils manifested by ultrasonication-enhanced fibril formation in","volume":"287","author":"Chatani","year":"2012","journal-title":"Trifluoroethanol J. Biol. Chem."},{"key":"10.1016\/j.biochi.2022.08.003_bib123","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/362553a0","article-title":"Human lysozyme gene mutations cause hereditary systemic amyloidosis","volume":"362","author":"Pepys","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.biochi.2022.08.003_bib124","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.revmed.2018.08.008","article-title":"L\u2019amylose \u00e0 lysozyme","volume":"40","author":"Scafi","year":"2019","journal-title":"Rev. Med. Interne"},{"key":"10.1016\/j.biochi.2022.08.003_bib125","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jphotobiol.2016.06.036","article-title":"Importance of fluorine in 2,3-dihydroquinazolinone and its interaction study with lysozyme","volume":"162","author":"Hemalatha","year":"2016","journal-title":"J.\u00a0Photochem. Photobiol. B Biol."},{"key":"10.1016\/j.biochi.2022.08.003_bib126","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.molstruc.2019.06.038","article-title":"The investigation of fluorine substitution in difluoroanilines with focus on 2,6-difluoroaniline by spectroscopic methods, density functional theory approach, and molecular docking","volume":"1196","author":"Kose","year":"2019","journal-title":"J.\u00a0Mol. Struct."},{"key":"10.1016\/j.biochi.2022.08.003_bib127","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.colsurfb.2018.11.047","article-title":"Fluorine-containing block\/branched polyamphiphiles forming bioinspired complexes with biopolymers","volume":"174","author":"Paiuk","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.biochi.2022.08.003_bib128","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0141-8130(03)00068-0","article-title":"Study of the interactions between lysozyme and a fully-fluorinated surfactant in aqueous solution at different surfactant\u2013protein ratios","volume":"33","author":"Ruso","year":"2003","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.biochi.2022.08.003_bib129","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/20\/22\/225106","article-title":"Synthesis and characterization of fluorinated magnetic core\u2013shell nanoparticles for inhibition of insulin amyloid fibril formation","volume":"20","author":"Skaat","year":"2009","journal-title":"Nanotechnology"},{"key":"10.1016\/j.biochi.2022.08.003_bib130","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bpc.2008.06.010","article-title":"Influence of fluorinated and hydrogenated nanoparticles on the structure and fibrillogenesis of amyloid beta-peptide","volume":"137","author":"Rocha","year":"2008","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.biochi.2022.08.003_bib131","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/cbic.201000237","article-title":"Controlling amyloid-beta peptide(1-42) oligomerization and toxicity by fluorinated nanoparticles","volume":"11","author":"Saraiva","year":"2010","journal-title":"Chembiochem : a Eur. j. chem. biol."},{"key":"10.1016\/j.biochi.2022.08.003_bib132","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1021\/acschemneuro.7b00015","article-title":"Fluorine functionalized graphene quantum dots as inhibitor against hIAPP amyloid aggregation","volume":"8","author":"Yousaf","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biochi.2022.08.003_bib133","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1006\/jmbi.1995.0395","article-title":"Conformational transitions in peptides containing two putative alpha-helices of the prion protein","volume":"250","author":"Zhang","year":"1995","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.biochi.2022.08.003_bib134","doi-asserted-by":"crossref","first-page":"23959","DOI":"10.1074\/jbc.M111.226688","article-title":"Hexafluoroisopropanol induces amyloid fibrils of islet amyloid polypeptide by enhancing both hydrophobic and electrostatic interactions","volume":"286","author":"Yanagi","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.biochi.2022.08.003_bib135","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1006\/jmbi.1996.0133","article-title":"Physical, morphological and functional differences between ph 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Abeta","volume":"256","author":"Wood","year":"1996","journal-title":"J.\u00a0Mol. Biol."}],"container-title":["Biochimie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908422001985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908422001985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:22:59Z","timestamp":1759540979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300908422001985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":135,"alternative-id":["S0300908422001985"],"URL":"https:\/\/doi.org\/10.1016\/j.biochi.2022.08.003","relation":{},"ISSN":["0300-9084"],"issn-type":[{"value":"0300-9084","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The current state of amyloidosis therapeutics and the potential role of fluorine in their treatment","name":"articletitle","label":"Article Title"},{"value":"Biochimie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biochi.2022.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}